Fig 2.

Landscape of most frequently mutated genes across the 66 patients with melanoma treated with BRAF inhibitors. (A) Each bar represents the total percentage of alterations found in each gene in either The Cancer Genome Atlas (TCGA) or Memorial Sloan Kettering/Vanderbilt cohort. P < .05 was considered significant. (B) BRAF mutations were found in all samples (100%), with three of 66 exhibiting coamplification of BRAF. Loss-of-function (LOF) mutations included deep deletions, nonsense mutations, and frameshift alterations predicted to result in early truncation and loss of expression.